March 2026 Research Update

This month added several different signals that MSA can be separated from similar conditions using body fluid tests, skin sampling, imaging, eye imaging, and even balance measurements. Across these studies, the pattern is not that one test solves diagnosis, but that combining a few different kinds of information may make the picture clearer, especially when symptoms overlap early on. The strongest findings were for alpha-synuclein testing in spinal fluid and skin, and for certain imaging patterns that help separate MSA from Parkinson's disease or related autonomic disorders. [1] [2] [3]

Several studies focused on detecting or classifying alpha-synuclein (a protein that clumps in MSA and Parkinson-type diseases) in ways that might help sort conditions that look alike. One study reported that a spinal fluid alpha-synuclein seed amplification test separated Lewy body diseases from MSA by different "seeding types," and that pairing this with a dopamine-related brain PET scan improved separation among PD, pure autonomic failure, and MSA subtypes. Another study reported that a two-site skin biopsy approach (neck plus distal leg) had very high sensitivity for detecting phosphorylated alpha-synuclein in people with Lewy body diseases and MSA, with the thigh site adding little. [1] [2]

Imaging and movement-based measurements also pointed toward measurable differences between MSA and look-alike conditions. A balance study in early disease used force-plate measurements and a machine learning model that reached 81.4% accuracy for separating PD from MSA-P, with eyes-closed balance differences standing out more between groups. A separate balance study found that usual quiet standing did not separate groups well, but dynamic standing did, with MSA showing a higher switching frequency in a model of balance control, which the study interpreted as a distinct control strategy from Parkinson's disease. [4] [5]

Two imaging studies suggested additional ways to distinguish subtypes and related disorders, but they measure different things. In people with MSA within about 2 years of onset, a dual-phase FP-CIT PET scan showed different patterns in MSA-P versus MSA-C, and some PET measures tracked with more severe motor findings. In a separate study looking across autonomic disorders, blood catechol testing by LC-MS/MS matched a reference method well, and using blood testing together with heart nerve PET imaging helped separate pure autonomic failure and PD with orthostatic hypotension from MSA. [3] [6]

Blood and spinal fluid protein panels continued to show promising but early signals for distinguishing MSA from PD. One study measuring 120 proteins reported that neurofilament light chain (NfL) was higher in MSA than controls in blood, and that several spinal fluid proteins (including NfL and others) were higher in MSA than PD, with some markers also tracking with severity. Smaller exploratory studies also reported group-level differences in synaptic proteins in spinal fluid (HOMER1 and NPTX2) and in blood vessel-related glycocalyx markers, and each reported that combinations of markers could help classify groups in their datasets. [7] [8] [9]

Two additional approaches aimed at early sorting of parkinsonism more broadly. A retina imaging study reported that people with MSA showed macular thinning patterns that differed from PSP and could help separate MSA from PD in its analyses. Another very large retrospective study used early clinical symptom timelines to predict postmortem diagnosis categories with an AUC of 0.83, showing that structured symptom histories may carry diagnostic information even without specialized lab tests, although this was not focused only on MSA. [10] [11]

A planned multicenter study protocol also appeared this month, showing where the field is heading. It will follow adults with REM sleep behavior disorder over 2 years to see whether patterns of phosphorylated alpha-synuclein in skin biopsies predict who later develops PD, DLB, or MSA, but no results are available yet. [12]

For patients and caregivers, the main change this month is that multiple research groups reported practical-looking ways to improve diagnostic confidence, especially when symptoms overlap with Parkinson's disease or autonomic disorders early on. Some findings may matter sooner than others: spinal fluid alpha-synuclein seeding patterns paired with brain PET and the two-site skin biopsy strategy were reported with strong separation or sensitivity in these datasets, while blood and spinal fluid protein panels and balance-based machine learning are still earlier and need more confirmation. What remains uncertain is how well these tools perform across different clinics and across the full range of MSA, and how best to combine them without adding too much testing burden. Even with those uncertainties, these studies help clarify that diagnosis is moving toward using a few complementary signals rather than relying on a single scan or symptom. [1] [2] [4]

This month strengthened the idea that some measurable markers can relate to how MSA affects thinking and how quickly the condition progresses, but the markers do not all behave the same way over time. One study tied a brain structure called the choroid plexus to cognitive differences in MSA, while another found that a single blood test level at baseline predicted later progression and major milestones. Together, these results add clarity that baseline or cross-sectional measures may carry useful information, even if repeated measurements do not always track step-by-step with change. [13] [14]

In an MRI study comparing MSA with and without mild cognitive impairment, the choroid plexus was larger in MSA than in healthy controls, and it was largest in the group with cognitive impairment. The same study reported more "free water" signal in this structure in the cognitively impaired group, and larger size and higher free water related to lower cognitive test scores. This points to a possible link between brain fluid handling and cognitive symptoms in MSA, but it does not show what causes what. [13]

A 4-year follow-up study reported that higher baseline plasma neurofilament light chain (NfL), a blood marker often linked to nerve cell injury, predicted faster worsening on MSA rating scales and higher risk of key milestones and death. In the same study, NfL levels over time did not move in step with progression, and the levels declined later in disease. This helps separate two ideas: a one-time early measurement may help with forecasting, while repeated NfL checks may not reflect day-to-day or month-to-month change. [14]

For patients, these studies mainly add understanding of why people with MSA can have different experiences over time, including differences in thinking and in speed of progression. The choroid plexus MRI findings are research-focused for now, but they help clarify that cognitive differences in MSA may have detectable brain correlates. The NfL study may matter sooner because it links an early blood test level to later outcomes, but it also makes clear that changes in NfL over time did not mirror symptom progression in that dataset. What remains uncertain is how these markers should be used across different MSA subtypes and stages, and whether they can reliably support individual-level planning in diverse real-world settings. [13] [14]

Only one treatment-focused report appeared this month, so the evidence is very limited and mainly illustrates what might be tested rather than what is proven to work. In one person with MSA and camptocormia (forward bending of the trunk), three non-invasive approaches were tried one after another, with different effects on walking, posture, and side effects. The case adds a concrete example of how symptom-targeted interventions can be measured with gait tools and posture tests, even though results may not apply to others. [15]

In this case, subcutaneous apomorphine improved walking speed and step length but caused nausea and low blood pressure. Repetitive trans-spinal magnetic stimulation improved one timed mobility measure without clear posture change. Botulinum neurotoxin injections to abdominal muscles were reported to provide the largest improvements in gait and posture measures in this individual. [15]

For patients and caregivers, this report is best read as an example of what one person experienced, not a guide to what will happen for others. It may matter later if similar approaches are studied in larger groups, because it shows that posture problems like camptocormia can be tracked with objective measurements and may respond differently to different interventions. What remains uncertain is which people with MSA might benefit, how long any benefit lasts, and how side effects compare across options when tested more broadly. [15]

This month added several laboratory and human-tissue studies that try to explain why MSA can differ from other alpha-synuclein diseases, and why it may vary from person to person. The shared picture is that alpha-synuclein can exist in different structural forms, and cells respond differently depending on the form and the pathways involved in clearing it. Other work pointed to immune activity and even viral genome integration as possible contributors in subsets of people, but these lines of evidence are still early. [16] [17] [18] [19]

Several experimental studies supported the idea that alpha-synuclein "strains" or polymorphs differ across diseases and may drive different downstream effects. One study comparing disease-derived fibrils reported that MSA-, PD-, and DLB-derived alpha-synuclein structures were distinct and linked to different protein interaction patterns and different resistance to cellular clearance pathways, with certain ubiquitin-proteasome system targets reducing inclusions in a strain-specific way. Another study in mice and test-tube preparations reported that even under similar conditions, alpha-synuclein aggregates can be conformationally diverse, and propagating these forms in mice produced different synucleinopathy patterns. [16] [17]

A separate laboratory study added an aging-related angle by changing the lipid makeup of membranes used during fibril formation. It reported that membranes resembling aged neurons produced fibrils with different structural signatures and weaker membrane association than fibrils formed with "normal" membrane mixtures, and that membrane-associated fibrils caused stronger cell pathology than lipid-free fibrils. This does not prove what happens in the human brain, but it supports the idea that the cellular environment can shape the kind of alpha-synuclein that forms. [20]

Immune profiling work suggested that the immune system may be more actively engaged in MSA than previously appreciated, at least in the studied groups. The study reported activated peripheral T cells in MSA with cytotoxic and inflammatory features, evidence that some T cells recognized alpha-synuclein in an HLA-dependent manner, and higher density of cytotoxic CD8+ T cells in the parietal cortex in postmortem MSA brains. These findings connect MSA biology to specific immune cell behaviors, but they do not yet show whether immune changes drive disease or react to it. [18]

Two method-building studies expand the tools available for future MSA biology research. One created and quality-checked induced pluripotent stem cell lines from 6 people with MSA and showed they can be differentiated into oligodendrocyte lineage cells, providing a human cell model tied to real patients. Another CRISPR screening study identified genes that changed phosphorylated alpha-synuclein aggregation after exposure to fibrils, reporting that activating OXR1 increased aggregation signals while reducing cellular energy measures, and that reducing EMC4 lowered aggregation signals by boosting cellular clearance pathways; some effects differed depending on fibril type. [21] [22]

One large genomic analysis raised the possibility that a subset of people with MSA may show evidence of partial HHV-6 genome integration more often than some other cohorts. This is an indirect finding from sequencing data and does not show infection, timing, or cause, but it points to a new direction researchers may test more directly. [19]

For patients, these studies mainly matter as groundwork for future diagnostics and treatments rather than something that changes care now. They help clarify why MSA is not simply "Parkinson's disease plus" by showing that alpha-synuclein can take distinct forms and interact with different cell cleanup systems, and that immune cells can show specific activation patterns in MSA. What remains uncertain is which of these biology findings will translate into reliable patient tests or new therapies, and whether they apply broadly across all people with MSA or only to certain subgroups. Even so, they make the research direction clearer by highlighting specific targets (cell clearance pathways, immune recognition, and patient-derived cell models) that can be tested in more applied studies. [16] [18] [21]

One single-patient report highlighted that MSA can sometimes come with unexpected test patterns, which can complicate diagnosis. It reinforces that individual results from imaging, spinal fluid tests, and genetics may not always align neatly, especially when rare genetic findings or overlapping syndromes are present. This report does not change what is typical, but it illustrates why clinicians may sometimes need more than one kind of evidence when a case looks unusual. [23]

One case described a person diagnosed with MSA-P who had a mixed picture across tests: brain metabolism imaging showed reduced cerebellar activity with normal striatal uptake, while dopamine transporter imaging showed severe, symmetric striatal dopamine transporter loss, and a spinal fluid alpha-synuclein seeding assay was negative. A pathogenic SPG4 mutation was also found, raising questions about whether more than one process contributed to the presentation. The report underlines that a negative spinal fluid seeding test can occur in an unusual presentation and that imaging patterns may vary. [23]

For patients and caregivers, this case mainly explains why the diagnostic journey can sometimes be confusing, with some tests pointing in different directions. A single unusual result, like a negative spinal fluid alpha-synuclein seeding test or an unexpected scan pattern, does not automatically settle the diagnosis either way, especially in rare mixed situations. What remains uncertain is how often findings like these occur and how much rare genetic variants such as SPG4 contribute in people diagnosed with MSA. The practical value right now is mostly in awareness that outlier cases exist and can motivate more careful, individualized evaluation in research and clinical discussions. [23]

One small quality-improvement pilot tried to reduce barriers to specialty care by arranging transportation and offering internet-enabled devices, but it did not show a clear improvement in transportation barriers over 6 months. The biggest message from this project is how difficult it can be to run access interventions in rapidly progressive conditions because many participants could not complete follow-up. Even without a strong positive result, the study clarifies what kinds of real-world obstacles future programs will need to address, including attrition and changing health status. [24]

Among 18 enrolled people with PSP, CBS, or MSA, only 7 completed 6-month follow-up, and no one reported lacking internet access so devices were not distributed. Transportation barrier scores changed very little between baseline and follow-up, while reported access to resources improved slightly. The study also reported health declines in the PSP subgroup during the same period, which likely made follow-up harder and complicates interpretation of any access measure changes. [24]

For patients and caregivers, this study is mainly about care delivery research rather than MSA biology or treatments. It suggests that simply arranging transportation may not be enough to measurably reduce access barriers in a short window, and it highlights how quickly circumstances can change for families, making long follow-up difficult. What remains uncertain is which kinds of support would make the biggest difference for people with MSA specifically, since the group mixed several diagnoses and many participants were lost to follow-up. Even so, it helps clarify that future access solutions will likely need to be flexible and resilient to health changes over time. [24]